iBio Announces Collaboration with EdgePoint AI for Next Gen Quality in Biologics Manufacturing
December 23 2019 - 8:30AM
iBio, Inc. (NYSE AMERICAN:IBIO) today announced that it has entered
into a collaboration with EdgePoint AI, a division of Mateon
Therapeutics, Inc. (OTCQB:MATN), to deploy EdgePoint’s proprietary
artificial intelligence (“AI”)/blockchain-driven vision system for
pharmaceutical manufacturing, known as TrustPoint Fabric. Initial
implementation will occur at iBio’s state-of-the-art production
facility for the optimization of raw material documentation and
verification activities.
Using blockchain technology, TrustPoint Fabric
enables automated data generation and capture to remain immutable
and fully auditable. Thus, when fully implemented, iBio aims to
deliver the highest-level of compliance to the pharmaceutical
industry’s standards for data integrity. Concurrently, the enhanced
automation capabilities are expected to lower operating costs while
improving quality for clients of iBio’s biologics contract
development and manufacturing services.
“We are proud to take part in efforts to bring
emerging technologies like TrustPoint Fabric into the
pharmaceutical manufacturing realm,” stated Robert Erwin, President
of iBio. “Adding this technology to our automated biologics
manufacturing facility is a natural fit and may yield substantial
benefits. The potential to reduce costs by streamlining labor
intensive manual operations while improving quality is very
attractive as we continue to grow our position as the leading
plant-based biologics CDMO.”
“We are excited that a leading plant-based CDMO
like iBio has chosen to pilot TrustPoint Fabric,” commented Vuong
Trieu, Ph.D., CEO of Mateon Therapeutics. “The platform has broad
application potential across virtually all types of pharmaceutical
manufacturing including biologics, cell and gene therapy, small
molecule manufacturing, bulk drug substance, fill finish, packaging
and labeling. Accordingly, and assuming everything goes as planned,
we envision the application of TrustPoint Fabric in iBio’s cGMP
manufacturing raw material supply chain will be the first in a
series of implementations, both with iBio as well as other
potential EdgePoint customers.”
About iBio
iBio, Inc., is a global leader in plant-based
biologics manufacturing.
Its FastPharming System™ combines
vertical farming, automated hydroponics, and glycan engineering
technologies to rapidly deliver gram quantities of high-quality
monoclonal antibodies, vaccines, bioinks and other proteins. The
Company’s subsidiary, iBio CDMO LLC,
provides FastPharming Contract
Development and Manufacturing Services via its 130,000 square foot
facility in Bryan, Texas. iBio CDMO also enables innovators to use
the FastPharming System for insourced
manufacturing via its Factory Solutions “design-and-build”
services.
iBio’s FastGlycaneering Development
Service™ includes an array of new glycosylation technologies for
engineering high-performance recombinant proteins. Additionally,
iBio is developing its own proprietary products which include its
lead asset, IBIO-100, for the treatment of fibrotic diseases. For
more information, visit www.ibioinc.com.
About EdgePoint AI
EdgePoint AI was established in order to advance
the company’s revolutionary cluster-computer platform for AI that
crunches machine learning models at a fraction of the power and
budget of mainstream computing in pharmaceutical manufacturing. The
company’s technology platform, called TrustPoint Fabric, provides
for an AI computing platform for pharmaceutical and healthcare
verticals, including blockchain support for manufacturing where
data integrity and security are of utmost importance. EdgePoint’s
management team is composed of executives with deep pharmaceutical
drug development, GMP manufacturing and AI knowledge.
FORWARD-LOOKING STATEMENTS
STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED
TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE
MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995.
SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS
COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND
THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY
ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND
DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS
THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN
THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE
COMMISSION.
Contact:Stephen Kilmer Investor
Relations (646) 274-3580 skilmer@ibioinc.com
iBio (AMEX:IBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024